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Abstract: Glucose-6-phosphate isomerase (GPI), also known as
phosphoglucose isomerase, was initially identified as the second gly-
colytic enzyme that catalyzes the interconversion of glucose-6-phos-
phate to fructose-6-phosphate. Later studies demonstrated that GPI was
the same as the autocrine motility factor (AMF), and that it mediates its
biological effects through the interaction with its surface receptor
(AMFR/gp78). In this study, we assessed the role of GPI/AMF as a
prognostic factor for clear cell renal cell carcinoma (ccRCC) cancer-
specific (CSS) and progression-free survival (PFS). In addition, we
evaluated the expression and localization of GPI/AMF and AMFR,
using tissue microarray-based immunohistochemistry (TMA-IHC),
indirect immunofluorescence (IF), and confocal microscopy analysis.
Primary renal tumor and nonneoplastic tissues were collected from
180 patients who underwent nephrectomy for ccRCC. TMA-IHC and IF
staining showed an increased signal for both GPI and AMFR in cancer
cells, and their colocalization on plasma membrane. Kaplan–Meier
curves showed significant differences in CSS and PFS among groups of
patients with high versus lowGPI expression. In particular, patients with
high tissue levels of GPI had a 5-year survival rate of 58.8%, as
compared to 92.1% for subjects with low levels (P< 0.0001). Similar, Silvano Palazzo ettocchi, MD,
Michele Battaglia, MD
In conclusion, our data suggest that GPI could serve as a marker of
ccRCC aggressiveness and a prognostic factor for CSS and PFS.
(Medicine 94(46):e2117)
Abbreviations: AMF = autocrine motility factor, AMFR =
autocrine motility factor receptor, ccRCC = clear cell RCC, CSS
= cancer-specific survival, ER = endoplasmic reticulum, ERAD =
ER-associated degradation, PFS = progression-free survival, PPP =
pentose phosphate pathway, RCC = renal cell carcinoma, GPI =
glucose-6-phosphate isomerase, ROC = receiver operating
characteristic, TMA = tissue microarrays.
INTRODUCTION
R enal cell carcinoma (RCC) accounts for approximately 2%to 3% of all adult malignancies, the highest incidence being
in Western countries. This disease comprises different histo-
pathological entities with specific clinical and biological
characteristics. Clear cell RCC (ccRCC) is the most common
subtype, accounting for 85% to 90% of renal malignancies.
Recent estimates have calculated that in 2015, 61,560 new cases
will be diagnosed (3.7% of all new cancer cases: 38,270 in men
and 23,290 in women) and 14,080 patients (2.4% of all cancer
deaths: 9070 men and 5010 women) will die of RCC in the
United States.1 Not only do nearly 30% of patients with RCC
present with metastatic disease, but also up to 30% of patients
who undergo surgery with curative intent will relapse with
disseminated disease.2 Recent studies have provided additional
insight into the molecular and cellular mechanisms involved in
RCC development and resistance to novel-targeted therapies.3–
5 Considering the natural history of this disease, we need to
identify novel biomarkers for early detection, risk assessment,
prediction of clinical outcome, and treatment response. A
prognostic role has been evaluated for several circulating
biomarkers associated with different features of RCC biology,
including carbonic anhydrase IX, C-reactive protein, CA15-3,
and some cancer metabolism-related proteins.6–11
The introduction of high-throughput techniques has led to
a more in-depth understanding of molecular bases underlying
the development of urologic cancers, as well as the identifi-
cation of novel biomarkers and potential therapeutic targets.12–
18 In this setting, analysis of the cancer metabolome has showna reprogramming of the cellular energy
o support continuous cell growth and
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RCC is fundamentally a metabolic disease.20 Many studies
have suggested that an altered metabolism is involved in the
development of this tumor.21–23 In addition, it has been shown
that many genes implicated in the RCC pathogenesis play an
important role in controlling cell metabolism.24,25
Glucose-6-phosphate isomerase (GPI), also known as
phosphoglucose isomerase, was initially identified as the sec-
ond glycolytic enzyme that catalyzes the interconversion of
glucose-6-phosphate to fructose-6-phosphate. Later studies
demonstrated that G6PI and the autocrine motility factor
(AMF) were the same, and that it mediated its biological effects
through the interaction with its surface receptor (AMFR/
gp78)26 (Fig. 1).
Recently, we showed that the flux of sugars through the
pentose phosphate pathway (PPP), in association with the
upregulation of some glucose metabolism-related enzymes
including GPI, promoted both cancer cell proliferation and
migration, as well as anabolic reactions in ccRCC.9 In the
present study, we assessed the role of GPI/AMF as a prognostic
factor for ccRCC cancer-specific (CSS) and progression-free
survival (PFS). In addition, we evaluated the expression and
localization of GPI/AMF and its surface receptor (AMFR/
gp78), using tissue microarray-based immunohistochemistry
(TMA-IHC), indirect immunofluorescence (IF), and confocal
microscopy analysis.
MATERIALS AND METHODS
Study Population and Tissue Collection
Primary renal tumor (n¼ 180) and nonneoplastic tissues
(n¼ 20) were collected from 180 patients who underwent
Lucarelli et alradical or partial nephrectomy for ccRCC between January
2007 and December 2014. Two pathologists confirmed the
presence of ccRCC in the neoplastic tissues and excluded tumor
FIGURE 1. The biological roles of GPI/AMF and AMFR. Glucose-6-p
second glycolytic enzyme that catalyses the interconversion of gluco
involved in tumor cell migration, invasion, and angiogenesis, and the
surface receptor (AMFR/gp78). In the mitochondria-associated endopla
is involved in the ER-associated protein degradation (ERAD) by cytos
2 | www.md-journal.comcells in the healthy specimens. Detailed clinical and pathologi-
cal characteristics of the patients are summarized in Table 1. All
patients were preoperatively staged by thoracoabdominal com-
puted tomography or magnetic resonance imaging. Tumor
staging was reassigned according to the seventh edition of
the AJCC-UICC TNM classification. The 2004 World Health
Organization and Fuhrman classifications were used to attribute
histological type and nuclear grade, respectively. Written
informed consent to take part was given by all participants.
The protocol for the research project has been approved by the
local Ethics Committee and conforms to the provisions of the
Declaration of Helsinki in 1995.
Real-Time PCR
Total RNA of normal and tumor tissue were reverse
transcribed with the high-capacity cDNA reverse transcription
kit (Applied Biosystems, Foster City, CA), following the man-
ufacturer’s instructions. Quantitative real-time polymerase
chain reactions (PCR) were performed using iQTM SYBR
Green Supermix buffer (6mM MgCl2, dNTPs, iTaq DNA
polymerase, SYBR Green I, fluorescein, and stabilizers)
(BIO-RAD Laboratories, Hercules, CA). The following primers
were used for real-time PCR: 50-GATCCTCCTGGC-
CAACTTCT-30 and 50-GTTGGTTGGGCGATTTCCTT-30 for
GPI/AMF; 50-AATCTGGCACCACACCTTCT-30 and 50-
AGCCTGGATAGCAACGTACA-30 for b-actin. Quantification
of the mRNA levels was performed on a MiniOpticon real-time
PCR detection system (BIO-RAD Laboratories). In the PCR
reactions, the following protocol was used: activation of the
polymerase at 958C for 3minutes, followed by 45 cycles at 958C
for 10 seconds, 608C for 30 seconds. Melting curves were
Medicine  Volume 94, Number 46, November 2015generated through 60 additional cycles (658C for 5 seconds
with an increment of 0.58C/cycle). Gene expression results
were obtained as mean Ct (threshold cycle) values of triplicate
hosphate isomerase (GPI)/autocrine motility factor (AMF), is the
se-6-phosphate to fructose-6-phosphate. Moreover, GPI/AMF is
se biological effects are mediated through the interaction with its
smic reticulum (ER), AMFR is also an E3 ubiquitin (Ub) ligase which
olic proteasomes.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinical and Pathological Characteristics
Variable nU 180
Age (years)
Median 52
95% CI 46–61.5
Gender
Male 110 (61%)
Female 70 (39%)
Dimensions (cm)
Median 5.5
95% CI 5–6.5
Pathological stage
pT1a 36 (20%)
pT1b 44 (24.4%)
pT2 52 (28.9%)
pT3 48 (26.7%)
pNþ 31 (17.2%)
cMþ 22 (12.2%)
Fuhrman grade
G1–2 112 (62%)
G3–4 68 (38%)
Follow-up
Median (months) 48
95% CI 42.8–53.1
Medicine  Volume 94, Number 46, November 2015CI¼ confidence interval.samples. Expression was determined using the 2DDCt method.
Expression values were normalized to b-actin.
Data Mining Using Oncomine Gene Expression
Microarray Datasets
GPI gene expression was analyzed using microarray gene
expression datasets deposited in the Oncomine database
(https://www.oncomine.org/resource/login.html). Firstly, to
address the differential expression of GPI/AMF between renal
cancer and normal tissues, combined filters were applied to
display the corresponding datasets. The Cancer Type was
defined as Clear Cell Renal Cell Carcinoma; Data Type was
mRNA; Analysis Type was Cancer versus Normal Analysis.The expression values of the GPI/AMF gene (log2 median-
centered intensity) were read from the displayed bar chart.
Student t test was used to calculate the significance.
Quantification of G6PI/AMF Protein in Tissue
Lysates
The MILLIPLEX MAP Human Glycolysis Pathway Mag-
netic Bead Panel (HGPMAG-27K, Millipore, Billerica, MA)
was applied in 96-well plates for the quantification of GPI/AMF
in tissue lysates. For the immunoassay procedures, 25ml of each
dilute lysate sample in assay buffer (5mg total protein/well) and
HeLa cells lysate (positive control) were added into wells in
duplicate, according to the manufacturer’s instructions. To each
well, 25ml of the mixed beads was added and the plate was
incubated for 2 hours at room temperature. Human glycolysis
pathway detection biotinylated antibodies were added for
1 hour; each captured a specific bead. After that, the reaction
mixture was incubated for 30minutes with streptavidin–PE
conjugate to complete the reaction on the surface of each
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.microsphere. Finally, the MILLIPLEX MAP was analyzed
by Luminex xMAP technology. The immunoassay on the sur-
face of each fluorescent-coded magnetic bead, MagPlex-C
microsphere, was identified and quantified based on fluorescent
signals. The median fluorescence intensity (MFI) was read with
the Luminex 200 instrument and measured with xPONENT
software.
Immunohistochemistry and Tissue Microarray
Construction
Nine high-density tissue microarrays (TMAs) were used
for GPI/AMF and AMFR immunostaining. Archived formalin-
fixed paraffin-embedded nephrectomy tissue samples for 180
cases were obtained. All tumor cores were identified by 2
uropathologists. These were selected by identifying represen-
tative tumor-containing slides and were used to assign the
original tumor grade in each case. Three-millimeter cores were
removed from the selected area (region of interest) using a
needle punch. These 3-mm donor cores were subsequently
embedded in previously arranged recipient paraffin blocks
through a precisely spaced 15-hole array pattern. Core positions
in the recipient paraffin block were noted on a TMA map. After
paraffin cooling, the recipient blocks were cut in the microtome
and used for immunohistochemistry. Immunohistochemical
evaluation of GPI/AMF and AMFR protein expression was
carried out on paraffin-embedded tissue sections. TMA were
deparaffinized and rehydrated through xylene and graded alco-
hol series. Slides were subjected to specific epitope unmasking
by microwave treatment (700W) in citrate buffer (0.01M pH
6.0). After antigen retrieval, TMA were incubated for 10min-
utes with 3% H2O2 to block endogenous peroxidase activity.
Sections were treated with serum-free protein block (Dako
Cytomation, Glostrup, Denmark) at room temperature (RT)
for 10minutes and then incubated: at 48C overnight with a
mouse anti-AMF (1:200, Novus Biologicals, Littleton, CO) and
at room temperature for 2 hours with a rabbit anti-AMFR
(1:100, Novus Biologicals). Binding of the secondary biotiny-
lated antibody was detected by the Dako Real EnVision Detec-
tion System, Peroxidase/DAB kit (Dako Cytomation),
according to the manufacturer’s instructions. Sections were
counterstained with Mayer’s hematoxylin (blue) and mounted
with glycerol (Dako Cytomation). Negative controls were
obtained by incubating serial sections with the blocking solution
and then omitting the primary antibodies. Staining of histologi-
cal sections was evaluated by optical light microscope using a
Leica microscope fitted with a Coolpix 990 digital camera
(Nikon). Protein immunoreactivity was scored on the extent
and intensity of staining, which was graded on an arbitrary scale
ranging from 0 to 3, with 0¼ negative, 1¼ low, 2¼medium,
and 3¼ high expression.
Immunofluorescence and Confocal Laser
Scanning Microscopy
Paraffin-embedded kidney sections were double-stained
for GPI/AMF (1B7D7, Novus Biologicals) and AMFR (Novus
Biologicals). The expression and localization of proteins was
evaluated by indirect immunofluorescence and confocal micro-
scopy analysis. After antigen unmasking, the sections were
blocked with 2% BSA in PBS for 1 h at room temperature.
Sections were incubated overnight at 48C with a primary
Autocrine Motility Factor in Renal Cell Carcinomaantibody against GPI (1:200 in blocking), followed by incu-
bation for 2 hours with the secondary antibody Alexa Fluor 555
goat anti-mouse (1:200; Molecular Probes, Eugene, OR).
www.md-journal.com | 3
FIGURE 2. GPI/AMF gene expression (Panel A) and protein levels (Panel B) evaluated by real-time PCR and Luminex xMAP1 technology,
gni
Lucarelli et al Medicine  Volume 94, Number 46, November 2015Sections were washed in PBS and then incubated for 2 hours
with primary antibodies against AMFR (1:100 in blocking)
followed by incubation for 1 hour at 378C with the secondary
antibody goat anti-rabbit IgG FITC (Novus Biologicals). All
sections were counterstained with TO-PRO-3 (Molecular
Probes). Negative controls were performed by omitting the
primary antibodies. Specific fluorescence was acquired by a
Leica TCS SP2 (Leica, Wetzlar, Germany) confocal laser-
scanning microscope using a 63 objective lens.
Statistical Analysis
Statistical calculations were performed with MedCalc
9.2.0.1 (MedCalc software, Mariakerke, Belgium) and PASW
18 software (PASW 18, SPSS, Chicago, IL). Comparisons of
median protein values between different groups were evaluated
by Mann–Whitney U test. Receiver operating characteristic
(ROC) curve analysis was performed to identify the GPI protein
expression cutoff for survival stratification.
In the CSS analysis, patients still alive or lost to
follow-up were censored, as well as patients who died of
RCC-unrelated causes. PFS was calculated from the date
of surgery to the date of disease recurrence. Estimates of
CSS and PFS were calculated according to the Kaplan–Meier
respectively. Normalized GPI/AMF mRNA and protein levels were si
with normal tissue.method and compared with the log-rank test. Univariate
and multivariate analyses were performed using the Cox
proportional hazards regression model to identify the most
TABLE 2. GPI/AMF Expression in ccRCC
Dataset Sample Set
Measured
Genes
ccRCC Samples
Examined
N
Gumz ccRCC vs Normal 12,624 10
Beroukhim Nonhereditary ccRCC
vs normal
12,624 27
Beroukhim Hereditary ccRCC
vs normal
12,624 32
Jones ccRCC vs normal 12,624 23
Lenburg ccRCC vs normal 17,779 9
Yusenko ccRCC vs normal 17,779 26
Data from 5 available datasets (Source: Oncomine, Compendia Bioscien
4 | www.md-journal.comsignificant variables for predicting CSS and PFS. A backward
selection procedure was performed with removal criterion
P> 0.10 based on likelihood ratio tests. Spearman test was
applied to evaluate the correlations between GPI and tumor
stage/size/grade. A P-value of <0.05 was considered statisti-
cally significant. Influence of the GPI on the predictive
accuracy of the multivariate models was determined by Harrell
concordance index.
RESULTS
GPI/AMF Expression Is Increased in Tumor Tissue
and Is a Risk Factor for RCC Progression and
Mortality
Detailed clinical and pathological characteristics of the
patients are summarized in Table 1. To analyze the transcription
levels, we firstly performed quantitative real-time PCR and
evaluated GPI/AMF mRNA levels in ccRCC tissue samples,
compared with normal renal parenchyma. GPI/AMF mRNA
levels are shown in Figure 2A. Normalized gene expression
levels for GPI/AMF were significantly higher in the ccRCC
compared with the normal tissue. To confirm the above findings
we analyzed the differential expression of GPI/AMF mRNA
ficantly higher in clear cell renal cell carcinoma (RCC) as comparedbetween renal cancer tissues and normal tissues by data mining
of the Oncomine microarray gene expression datasets27–31
(Table 2). Overall, we found that GPI/AMF expression was
ormal Samples
Examined
Fold
Change P-Value
Overexpression
Gene Rank Refs.
10 1.623 1.93E–5 677 (in top 6%) 27
11 1.638 3.75E–10 175 (in top 2%) 28
11 1.661 5.17E–13 120 (in top 1%) 28
23 1.950 3.35E–4 3394 (in top 27%) 29
9 1.806 0.048 4343 (in top 25%) 30
3 2.243 1.05E–4 1014 (in top 6%) 31
ce, Ann Arbor, MI).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. Comparisons of tissue GPI median values
stratified according to clinical stage (Panel A) and between
patients with or without lymph node metastases (Panel B)
Autocrine Motility Factor in Renal Cell Carcinomasignificantly upregulated in ccRCC comparing with normal
tissues.
Next, we analyzed the GPI protein levels and the results
were consistentwith the gene expression levels. In particular, GPI
protein levels were significantly higher in RCC patients than in
healthy subjects (P< 0.0001) (Figure 2B). Statistically signifi-
cant differences resulted between GPI values and clinical stage
(P< 0.0001; Spearman correlation: rs¼ 0.61, P< 0.0001),
lymph node involvement (P< 0.0001), and visceral metastases
(P< 0.0001) (Fig. 3). No correlation was found between protein
levels and tumor size (P¼ 0.38) or Fuhrman grade (P¼ 0.48).
To evaluate the association between patients survival and
the expression levels of GPI (protein expression in tissue
lysates), we classified the entire population by high versus
low expression levels according to the cut-offs obtained with
ROC curve analysis. After a median follow-up of 48 months
(95% CI: 42.8–53.1), 20 patients had died of ccRCC. Kaplan–
Meier survival curves for CSS and PFS, stratified by the GPI
tissue levels, are shown in Figure 4. Both CSS and PFS were
significantly decreased in patients with high levels of GPI/
AMF. Univariate analysis for the predefined variables showed
that pathological stage, presence of nodal and visceral metas-
tases, Fuhrman grade, presence of necrosis, tumor size, and high
levels of GPI were significantly associated with the risk of death
(Table 3) and progression (Table 4). At multivariate analysis by
Cox regression modeling, pathological stage, presence of nodal
and visceral metastases, Fuhrman grade, and high levels of GPI,
were independent adverse prognostic factors for CSS (Table 3)
and PFS (Table 4). Regarding CSS, the c-index of the multi-
variate model without GPI was 0.81 compared with 0.84 when
GPI was supplemented. For PFS, the c-index improved from
0.73 compared with 0.77 when the GPI was added.
Distribution Pattern of GPI/AMF and AMFR in
Normal and Tumor Tissues
Finally, to visualize the location and expression of GPI/
AMF and AMFR, we performed immunohistochemistry on
normal and pathological tissues, using high-density TMAs.
Normal kidney showed weak staining for GPI, predominantly
localized in the cytoplasm of renal tubule cells, whereas it was
not detected in the glomeruli (Fig. 5A). Instead, ccRCC showed
a stronger staining in cancer cells, with both a cytoplasmic and
membranous pattern (Fig. 5B and C). Similarly, AMFR expres-
sion was very low in normal kidney (Fig. 5D), but showed
higher levels in tumor tissue (Fig. 5E and F). TMA evaluation
showed GPI protein expression in 100% of cases, with high
expression levels in 93 (51.6%) cases. AMFR was expressed at
high levels only in 11 (6.1%) cases and unlike GPI, the receptor
was not detectable in 35 (19.4%) patients (Fig. 5G).
To confirm these findings, we analyzed GPI–AMFR
coexpression in the normal and neoplastic renal tissue samples
(Fig. 6). In particular, immunofluorescence staining showed an
increased signal for both GPI and AMFR in cancer cells, and
their colocalization on plasma membranes (Fig. 6D–I). Inter-
estingly, GPI was detected both inside and outside the cancer
cells, in accordance with its multifunctional role as a cytosolic
enzyme and extracellular cytokine.
DISCUSSION
Medicine  Volume 94, Number 46, November 2015GPI/AMF is a multifunctional protein that plays a dual
role, both inside and outside the cell. Inside the cell, GPI
functions as a cytosolic glycolytic enzyme that catalyzes the
and with or without visceral metastases (Panel C). GPI/AMF
median values were significantly higher in patients with
advanced disease, with lymph node involvement and visceral
metastases.
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FIGURE 4. Kaplan–Meier cancer-specific survival (CSS) and progression-free survival (PFS) curves, stratified by GPI/AMF tissue levels.
Patients with high tissue levels of GPI/AMF had reduced CSS (Panel A) and PFS (Panel B) as compared with patients with lower values.
TABLE 3. Univariate and Multivariate Analyses for Cancer-Specific Survival
Univariate Multivariate
Variable Category HR (95% CI) P-Value HR (95% CI) P-Value
T stage T3 vs T1/2 3.91 (2.82–4.63) 0.003 1.72 (1.12–2.63) 0.01
N stage Nþ vs N0 8.41 (6.20–10.32) 0.001 3.36 (2.43–4.32) 0.001
M stage Mþ vs M0 9.22 (8.31–14.81) 0.001 6.22 (4.12–10.31) 0.001
Grade G3/4 vs G1/2 2.63 (1.12–6.53) 0.01 1.34 (1.02–2.23) 0.01
Necrosis Yes vs no 2.21 (1.36–3.41) 0.001 — —
Tumor size Continuous 1.18 (1.03–1.34) 0.01 — —
GPI Continuous 1.21 (1.10–1.61) 0.0001 1.26 (1.04–1.88) 0.001
CI¼ confidence interval, GPI¼ glucose-6-phosphate isomerase, HR¼ hazards ratio.
TABLE 4. Univariate and Multivariate Analyses for Progression-Free Survival
Univariate Multivariate
Variable Category HR (95% CI) P-Value HR (95% CI) P-Value
T stage T3 vs T1/2 5.12 (2.85–9.30) 0.001 4.08 (2.25–7.41) 0.001
N stage Nþ vs N0 3.26 (1.08–6.52) 0.01 2.82 (1.08–6.34) 0.02
M stage Mþ vs M0 4.04 (2.02–6.18) 0.0001 2.04 (1.01–3.29) 0.001
Grade G3/4 vs G1/2 3.38 (1.51–7.63) 0.003 2.26 (1.18–5.34) 0.01
Necrosis Yes vs no 1.18 (1.02–1.43) 0.01 — —
Tumor size Continuous 1.12 (0.99–1.27) 0.02 — —
GPI Continuous 1.17 (1.05–1.36) 0.0001 1.16 (1.02–1.65) 0.01
ha
Lucarelli et al Medicine  Volume 94, Number 46, November 2015isomerization of glucose 6-phosphate to fructose 6-phosphate,
and it is involved in the recycling of hexose-6-phosphate in the
PPP. In addition to its role in cellular metabolism, outside the
cell, GPI/AMF acts as a cytokine, and this function is dependent
CI¼ confidence interval, GPI¼ glucose-6-phosphate isomerase, HR¼on the interaction with its membrane receptor, AMFR/
gp78.26,32 In particular, GPI/AMF plays a role as a maturation
factor for human myeloid leukemia cells, is a neurotrophic
6 | www.md-journal.comfactor for embryonic spinal and sensory neurons, is involved in
sperm agglutination, is a myofibril-bound serine proteinase
inhibitor, and has a role in the development of somatosensory
and motoric neural structures.33–37
zards ratio.AMFR/gp78 is a putative seven transmembrane G protein-
coupled receptor that stimulates cell motility after binding with
GPI/AMF. This protein is also located on the mitochondria-
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 5. Immunohistochemical staining of GPI/AMF and AMFR proteins in tissue microarrays of human clear cell renal cell carcinoma
(RCC) specimens. In normal kidney, GPI was predominantly localized in the cytoplasm of renal tubule cells, whereas it was absent in the
glomeruli (Panel A). Clear cell RCC showed a stronger staining in cancer cells, with both a cytoplasmic and membranous pattern (Panels B
and C). Similarly, AMFR expression was very low in normal kidney (Panel D), but showed higher levels in tumor tissue (Panels E and F). Heat
ane
Medicine  Volume 94, Number 46, November 2015 Autocrine Motility Factor in Renal Cell Carcinomaassociated endoplasmic reticulum (ER) where it functions as a
ubiquitin E3 ligase involved in the ER-associated degradation
(ERAD) of proteins.
Many studies have shown that GPI/AMF and AMFR are
overexpressed in some tumors, have a role in cancer pro-
gression and are negatively associated with patients’ clinical
outcome.9,38–40 In a recent study, we explored the role of
glycolysis and PPP in ccRCC and evaluated the activation
of the GPI–AMFR axis in this tumor.9 In particular, we found
that GPI was overexpressed in ccRCC, in association with high
levels of glucose 6-phosphate and fructose 6-phosphate. More-
over, by in vitro and in vivo assays we showed that AMFR was
involved in renal cancer cell migration, invasion, and tumor
angiogenesis.9
In the present study performed in a large cohort of patients
using quantitative real-time PCR and data mining of public
Oncomine microarray datasets,27–31 we found that GPI/AMF
mRNA was upregulated in ccRCC. Moreover, both the GPI/
AMF and AMFR proteins were overexpressed in renal cancer
tissue compared to normal kidney. In accordance with its
map summarizing GPI and AMFR staining in 180 RCC patients (Pbiological role, GPI was also identified outside the tumor cells
and costained with AMFR, indicating the colocalization with its
membrane receptor.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Several reports have demonstrated that both GPI/AMF and
AMFR expression are associated with a poor clinical outcome
in some tumors. Jiang et al38 showed that GPI and AMFR were
highly expressed in human breast cancer and were associated
with reduced disease-free survival and CSS. Similarly, an
increased GPI expression was associated with a higher meta-
static potential in human lung carcinoma.39 In addition, a recent
study showed that GPI/AMF levels were significantly increased
in the serum and in neoplastic tissue of patients with endo-
metrial carcinoma.40 In this scenario, to address the significance
of GPI/AMF in ccRCC prognosis, we stratified the patients’
population according to protein expression levels. Kaplan–
Meier curves showed significant differences in CSS and PFS
between the patients groups with high versus low protein
expression. In particular, patients with high tissue levels of
GPI had a 5-year survival rate of 58.8%, as compared to 92.1%
for subjects with low levels (P< 0.0001). Similar findings were
observed for PFS (56.8% vs 93.3% at 5 years). These findings
are in accordance with the results of other studies that showed
how low expression of GPI contributes to the aggressive
l G). Original magnifications 20.phenotype of different types of cancer cells.41–43
Multivariate analyses showed that high levels of GPI
(HR¼ 1.26; P¼ 0.001) together with pT stage> 2, Fuhrman
www.md-journal.com | 7
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Lucarelli et al Medicine  Volume 94, Number 46, November 2015grade 3, and presence of nodal and visceral metastases, were
significantly predictive of risk of death. Similarly, this marker
remained an independent prognosticator of outcome in terms of
PFS (HR¼ 1.16; P¼ 0.01). Some studies have demonstrated
that GPI/AMF expression is associated with increased tumor
cell motility and metastatic potential.26,44,45 In agreement with
these results, we found increased levels of GPI in metastatic
tumors compared to localized cancers. In fact, GPI protein
expression levels were significantly increased in patients with
lymph node (P< 0.0001) and visceral metastases (P< 0.0001).
FIGURE 6. Immunofluorescence and confocal laser scanning micr
renal cell carcinoma (RCC) specimens (Panels D–I). Immunofluores
cancer cells, and their colocalization on plasma membranes (PaneIt has been shown that GPI–AMFR axis inhibition blocks the
development of the metastatic phenotype and the migratory
tumor cell capacity.42 In a recent study, we demonstrated that
8 | www.md-journal.comccRCC cell treated with anti-AMFR antibody, had reduced
migratory and invasive capabilities, and a decreased neoangio-
genic response.9 Therefore, blocking this axis may serve as a
putative therapeutic target for ccRCC.
The main limitations of this study include the single-center
design of the report, and its retrospective nature.
In conclusion, the evidence supported the role of the GPI–
AMFR axis in ccRCC progression, possibly via autocrine/
paracrine mechanisms. Moreover, we provide a detailed
description of GPI expression in ccRCC and discuss some
opy of GPI/AMF and AMFR in normal (Panels A–C) and clear cell
ce staining showed an increased signal for both G6PI and AMFR in
and I).clinical implications. In particular, we found that GPI could
serve as a marker of ccRCC aggressiveness and a prognostic
factor for CSS and PFS.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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